Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in AF with bioprosthetic mitral valves (RIVER)
NCT02303795Phase 2Completed
- Sponsor
- HCor
- Start
- Aug 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib), sponsored by HCor. Primary endpoint: Major Clinical Events at 12 months. Started Aug 2015; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02303795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303795.